MultiCell Technologies, Inc. (MCET.OB) is 'One to Watch'

The company’s drug development program focuses on the modulation of the immune system. Their lead drug candidates include drugs to treat multiple sclerosis (MS)-related chronic fatigue, relapsing-remitting MS, type-1 diabetes, and infectious disease. MultiCell Technologies, Inc.’s therapeutic pipeline includes MCT-125, which is directed at treating chronic fatigue in MS patients. MCT-125 completed a 138 patient Phase II clinical trial and demonstrated strong efficacy in reducing fatigue in MS patients.

The company also has their MCT-175, a targeting relapse-remitting MS. MCT-175 targets disease specific autoaggressive T-cells that destroy the myelin sheath of nerve cells. It is in preclinical development for the treatment of relapsing-remitting MS. MultiCell has their MCT-275 for the treatment of type-1 diabetes. MCT-275 targets disease-specific autoaggressive T-cells that destroy insulin-producing cells in the pancreas. It is also in preclinical development.

In addition, the company has their MCT-465, which addresses Influenza A infection. MCT-465 in preclinical studies successfully reduced pulmonary influenza virus levels 1,000-fold in animal models. It has demonstrated effectiveness in reducing virus levels of HIV and HCV in animal models.

MultiCell also specializes in developing primary cell immortalization technologies to produce therapeutic proteins as well as cell-based assay systems for use in drug discovery. Their immortalized human hepatocyte BioFactoriesâ„¢ continues to secrete a range of proteins. These include clotting factors and alpha-1-antitrypsin that are virtually indistinguishable from plasma-derived proteins. MultiCell looks for strategic partners to co-develop genetically engineered producer cells that secrete correctly processed proteins in mass culture.